Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung disease and PKCs.

Edward C Dempsey1, Carlyne D Cool, Cassana M Littler

  • 1Cardiovascular Pulmonary Research Laboratory, University of Colorado Health Sciences Center, Denver, CO 80262, USA. edward.dempsey@uchsc.edu

Pharmacological Research
|June 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Connexin 43 Loss in Endothelial Progenitors Facilitates Functional Airway Adaptation After Lung Injury.

Research square·2026
Same author

IPF AT2 cells are stuck in transition and biophysically dysfunctional.

bioRxiv : the preprint server for biology·2026
Same author

Authors' Response to Silicosarcoidosis: Do We Really Need Hybrid Labels That May Undermine Occupational Disease Recognition?

American journal of industrial medicine·2026
Same author

Quantitative lung particulate analysis links increased anthracotic pigment burden to burn pit exposure in post-9/11 veterans with distal lung disease.

Scientific reports·2025
Same author

Ectopic expression of MUC5B in the respiratory bronchiole initiates endoplasmic reticulum stress in the IPF lung.

American journal of respiratory cell and molecular biology·2025
Same author

Study Design and Rationale for The Breathe Easier With Tadalafil Therapy for Exercise-Related Dyspnea in COPD-PH (BETTER COPD-PH).

Pulmonary circulation·2025
Same journal

Loss of ETV4 triggers PPM1E downregulation and AMPK-ULK1-dependent autophagy to promote intrinsic trametinib resistance in breast cancer.

Pharmacological research·2026
Same journal

Editorial: Current pharmacological challenges of Treatment-Resistant Depression.

Pharmacological research·2026
Same journal

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research·2026
Same journal

Sinomenine regulates the AKT/FOXO3/GLUL pathway to inhibit pulmonary fibroblast-to-myofibroblast transition via α7nAChR against rheumatoid arthritis associated interstitial lung disease.

Pharmacological research·2026
Same journal

Ketohexokinase: A central mediator of fructose-associated pathogenesis and promising therapeutic target.

Pharmacological research·2026
Same journal

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies.

Pharmacological research·2026
See all related articles

Protein kinase C (PKC) isozymes are crucial in lung cellular responses and diseases. Targeting specific PKC isozymes offers a promising therapeutic strategy for various pulmonary disorders.

Area of Science:

  • Pulmonary Medicine
  • Molecular Biology
  • Pharmacology

Background:

  • Protein Kinase C (PKC) isozymes play vital roles in numerous lung cellular processes.
  • Existing therapies for pulmonary disorders are often inadequate, highlighting the need for novel treatment strategies.
  • The lung's complex structure and heterogeneous cell composition present unique challenges for therapeutic interventions.

Purpose of the Study:

  • To explore the therapeutic potential of targeting protein kinase C (PKC) isozymes in the lung.
  • To identify key PKC isozymes involved in lung pathophysiology and associated diseases.
  • To review current and emerging therapeutic approaches for targeting PKCs in lung disorders.

Main Methods:

  • Analysis of PKC isozymes in normal and diseased human lung tissue and cells.

Related Experiment Videos

  • Utilizing isolated organ preparations and whole animal studies, including genetically engineered mice.
  • Investigating mechanisms regulating PKC activity, such as phosphorylation and interactions with binding proteins.

    • Main Results:

    • PKCs are implicated in various lung disorders, including edema, pulmonary hypertension, asthma, COPD, and fibrosis.
    • Heterogeneity in cellular responses and counter-regulatory effects of PKC isozymes necessitate targeted or combination therapies.
    • Dysregulation of PKC signaling contributes to pathological changes in endothelial, smooth muscle, and epithelial cells.

    Conclusions:

    • Targeting specific PKC isozymes presents a promising avenue for developing novel therapies for lung diseases.
    • Combination therapies, targeting multiple PKC isozymes or integrating with other pathway inhibitors, may enhance efficacy.
    • Understanding PKC regulation and isozyme-specific functions is critical for advancing pulmonary medicine.